BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mylan Pharmaceuticals, Inc. (MYL) Recalls Two Drugs Due to Dangerous Label Mix-up


3/18/2011 6:55:18 AM

TORONTO, ONTARIO--(Marketwire - 03/17/11) - Mylan Pharmaceuticals ULC in Canada today announced that it is voluntarily recalling all 100-count bottles of a single product lot, number 1037180, which were distributed to wholesalers and pharmacies. The company received a report from a pharmacist who had received several bottles of Mylan-Minocycline Capsules, 50 mg, including one bottle that was mislabeled as another product (Mylan-Amlodipine Tablets, 5 mg). The mislabeled bottle did contain Mylan-Minocycline Capsules, 50 mg. The company has notified Health Canada of this action. The 250-count bottles that were distributed to wholesalers and pharmacies with the same lot number are not part of this recall.

Mylan Pharmaceuticals ULC President Dick Guest said: "We are recalling this product because patient safety is of utmost concern for all of us at Mylan. There can be a risk of an adverse event if any patient mistakenly takes a medication that has not been prescribed for them. In some cases, these risks can be serious, depending on the product and the individual patient."

With any medication recall, all licensed health care professionals in Canada are required to follow drug product recall instructions provided by Health Canada. Mylan also is in the process of contacting pharmacists who may have received product from this lot and is advising them to contact patients who had an Amlodipine prescription filled on or after Sept. 13, 2010, the date when this Minocycline lot was released to the Canadian market, to ensure that they did not receive mislabeled product. Patients should contact their pharmacists and/or physicians if they have any questions.

Mylan-Minocycline, a generic version of Minocin®, is an antibiotic indicated for the treatment of various types of infections. Mylan-Amlodipine, a generic version of Norvasc®, is used to treat hypertension (high blood pressure) and angina (chest pain).

Customers or patients who have additional questions should call Mylan Pharmaceuticals ULC Customer Service at 1.800.575.1379. Contact:

Contacts: CONTACTS: Michael Laffin (Media) 724.514.1968 Kris King (Investors) 724.514.1813

Read at BioSpace.com
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES